Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ASML Holding NV (ASML) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ASML Holding NV — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while ASML Holding NV trades at $1,772.5 (market cap $662.67B). The key difference: ASML Holding NV is far larger — about 147.6× ACADIA Pharmaceuticals Inc.'s market cap, and ASML Holding NV pays a 0.5% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ASML | |
|---|---|---|
Market Cap | $4.49B | $662.67B |
Sector | Health | Technology |
52-Week High | $28.06 | $1.99K |
52-Week Low | $20.06 | $689.63 |
Enterprise Value | $3.69B | $656.21B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ASML trades at $1,747.28, down 1.25% amid semiconductor sector volatility. The stock shows strong fundamentals with 2025 revenue of $32.67B and net income of $9.61B, supported by robust profitability margins. Technical indicators are neutral, with support near $1,748. Recent news highlights AI-driven demand and geopolitical risks in chip supply chains.
Outlook remains positive given ASML's monopoly in EUV lithography and analyst consensus price target of $2,210. Risks include cyclical semiconductor demand and geopolitical tensions. Earnings beat in Q1 2026 reinforces growth trajectory, but high valuations require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →
